Acute Ischemic Stroke AISPhase 1STEVIANCT06995625
The STem Cell-derived Extracellular Vesicle Therapy In Acute Ischemic Stroke (STEVIA)
A Phase 1 study testing SNE-101 in people with Acute Ischemic Stroke AIS, run by S&Ebio Co. Ltd. at 3 sites in South Korea.
Trial summary
This is a multicenter open-label, single-arm, dose escalation phase I clinical trial to evaluate the safety and tolerability of SNE-101 in patients with acute ischemic stroke Read more about this study
- Who is it for?
- Ages 19 years and older
- Conditions the study is for
- Acute Ischemic Stroke AIS
- What is being tested?
- SNE-101
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 18 participants
- Where
- 3 sitesSouth Korea
- Study dates
- 22 Jun 2026to 31 Mar 2027
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults with 19 years or older
- Patients within 5 days of symptom onset who have not received thrombolytic therapy or undergone endovascular reperfusion procedures.
- Patients within 5 days of symptom onset who have received thrombolytic therapy or undergone endovascular reperfusion procedures but show no clinical recovery after 2 days of observation.
- Imaging findings must meet both of the following:
- Infarction within the middle cerebral artery territory on diffusion-weighted imaging (DWI)
- Infarct size ≥ 20 mm in the longest diameter on DWI
Show all 11Show fewer
- Neurological status meeting all three of the following NIHSS criteria:
- Moderate to severe neurological deficit (NIHSS score between 5-21)
- New onset of motor weakness (score 2-4 in at least one of NIHSS items 5a, 5b, 6a, or 6b)
- No impaired consciousness (score 0-1 on NIHSS items 1a, 1b, and 1c)
- Voluntary written informed consent
Who cannot join
- Subjects are ineligible if they meet any of the following:
- Pre-stroke disability (pre-stroke mRS ≥ 2)
- Likely to recover spontaneously, based on all three of:
- No longer meeting the NIHSS inclusion criteria 48 hours post-thrombolysis or endovascular therapy
- Lacunar stroke due to small vessel occlusion
- SAFE (Shoulder Abduction and Finger Extension) score ≥ 5
Show all 21Show fewer
- Presence or risk of malignant middle cerebral artery infarction with brain edema
- Significant medical history within the past 5 years:
- Severe heart failure
- Severe infectious disease
- Severe hepatic failure or renal failure
- Newly diagnosed or actively treated cancer
- Any systemic disease deemed by investigator to significantly reduce life expectancy
- Any condition likely to hinder follow-up during the study
- Diagnosed severe psychiatric illness:
- Moderate or greater depression pre-stroke with functional impairment and suicide risk
- Pre-stroke dementia interfering with daily living (CDR ≥ 2)
- Contraindication to MRI (e.g., pacemaker)
- Pregnant or breastfeeding, or unwilling to use effective contraception method for 90 days after last dose.
- Participation in another clinical trial within the past 3 months
- Any other reason determined by the investigator that would prevent participation
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
South Korea3 sites, 3 recruiting
- Recruiting
Samsung Medical Center
Seoul, 06351
Woo-Keun Seo, MD
Jong-Won Chung, MD
- Recruiting
Ewha Womans University Seoul Hospital
Seoul, 07804
Tae-Jin Song, MD
- Recruiting
Ajou University Hospital
Suwon, Gyeonggi-do, 16499
Jin soo Lee, MD
About this study
Official title: An Open-Label, Single-Arm, Dose Escalation Phase I Clinical Trial to Evaluate the Safety and Tolerability of SNE-101 in Patients With Acute Ischemic Stroke
This is a multicenter open-label, single-arm, dose escalation phase I clinical trial to evaluate the safety and tolerability of SNE-101 in patients with acute ischemic stroke
Read the detailed description
The study aims to assess the safety, tolerability, and preliminary efficacy of allogeneic Wharton's jelly-mesenchymal stem cell-derived extracellular vesicles (EVs) in patients with acute ischemic stroke.
- Conditions
- Acute Ischemic Stroke AIS
- Being tested
- SNE-101
- Keywords
- Stroke, Exosome, Extracellular vesicles, Wharton's jelly-mesenchymal stem cell, MSC
- Medical subject headings
- Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SNE-101Drug
Experimental: Cohort 1 - SNE-101 4.8 × 10e10 particles (n=3 to 6) Experimental: Cohort 2 - SNE-101 9.6 × 10e10 particles (n=3 to 6) Experimental: Cohort 3 - SNE-101 19.2 × 10e10 particles (n=3 to 6)
| Study group | Role | What they receive |
|---|---|---|
| SNE-101 | Experimental | Patients will be given SNE-101, an extracellular vesicle derived from Wharton's jelly mesenchymal stem cells.
• Drug: SNE-101
* Three multiple doses of SNE-101 will be administered to three study cohorts , each consisting of 3 to 6 subjects.
* SNE-101 will be administered intravenously once a day for 5 days. Receives: Drug: SNE-101 |
What is being measured
The primary outcome is the main question the study is designed to answer.
To evaluate the safety and tolerability of SNE-101 in patients with acute ischemic stroke and determine the Maximum Tolerated Dose (MTD)
- The Maximum Tolerated Dose (MTD) determination via the Dose limiting toxicity (DLT)
Measured: MTD: within 19 days after first dose
To evaluate the safety and tolerability of SNE-101 in patients with acute ischemic stroke and determine the Maximum Tolerated Dose (MTD)
- Adverse events are monitored continuously throughout the study.
Measured: Adverse events: 180 days
Secondary outcomes (5)
To assess the efficacy of SNE-101 in patients with acute ischemic stroke.
- Mean % change in Fugl-Meyer Assessment (FMA) from baseline to Week 13
A quantitative measure used to assess motor function, balance, and joint motion in post-stroke patients. The FMA is a widely validated scale used to evaluate sensorimotor recovery, especially in the upper and lower extremities, with a maximum score of 226 indicating normal function. Higher scores indicate better motor recovery.
Measured: 13 weeks
To assess the efficacy of SNE-101 in patients with acute ischemic stroke.
- Improvement in neural tract integrity on Diffusion Tensor Imaging (DTI) from baseline to Week 13.
An advanced MRI technique used to assess the integrity and organization of white matter tracts in the brain. DTI parameters such as fractional anisotropy (FA) and mean diffusivity (MD) provide quantitative measures of axonal regeneration and neuroplasticity. Increases in FA and normalization of MD values are indicative of neural recovery after stroke.
Measured: 13 weeks
To assess the efficacy of SNE-101 in patients with acute ischemic stroke.
- Changes in NIH stroke scale (NIHSS) from baseline to Week 13
A standardized neurological examination that quantifies the severity of neurological impairment caused by stroke. The NIHSS evaluates several domains including consciousness, motor strength, language, vision, and sensory loss. Scores range from 0 to 42, with lower scores indicating milder neurological deficits.
Measured: 13 weeks
To assess the efficacy of SNE-101 in patients with acute ischemic stroke.
- Changes in modified Rankin Score (mRS) from baseline to Week 13
A global functional outcome scale that assesses the degree of disability or dependence in daily activities in patients who have suffered a stroke. Scores range from 0 (no symptoms) to 6 (death). Lower scores indicate greater functional independence and are commonly used as primary endpoints in stroke trials.
Measured: 13 weeks
To assess the efficacy of SNE-101 in patients with acute ischemic stroke.
- Changes in Infarct size from baseline to Week 13
The volume of cerebral infarction measured using MRI sequences such as diffusion-weighted imaging (DWI) and fluid-attenuated inversion recovery (FLAIR). Reduction in infarct growth or final infarct size is considered an imaging biomarker of neuroprotection. Measurements are expressed in cubic centimeters (cc) and compared over time to assess treatment efficacy.
Measured: 13 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 May 2025
- Study start22 Jun 2026
- Primary completion31 Mar 2027 (estimated)
- Study completion31 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Ischemic Stroke AISStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 18 participants (estimated)
Sponsor and investigators
- Lead sponsor
- S&Ebio Co. Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06995625
- Sponsor's protocol ID
- SNE-101S
- Acronym
- STEVIA
- Status last verified
- Jul 2026
- First submitted
- 13 May 2025
- Last updated
- 6 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-Label, Single-Arm, Dose Escalation Phase I Clinical Trial to Evaluate the Safety and Tolerability of SNE-101 in Patients With Acute Ischemic Stroke
- ClinicalTrials.gov ID
- NCT06995625
- Acronym / sponsor ID
- STEVIA / SNE-101S
- Conditions
- Acute Ischemic Stroke AIS
- Keywords
- Stroke, Exosome, Extracellular vesicles, Wharton's jelly-mesenchymal stem cell, MSC
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 18 participants (estimated)
- Lead sponsor
- S&Ebio Co. Ltd.Industry (pharma, biotech, devices)
- Study start
- 22 Jun 2026 (actual)
- Primary completion
- 31 Mar 2027 (estimated)
- Study completion
- 31 Mar 2027 (estimated)
- First posted
- 29 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a multicenter open-label, single-arm, dose escalation phase I clinical trial to evaluate the safety and tolerability of SNE-101 in patients with acute ischemic stroke
Detailed description
The study aims to assess the safety, tolerability, and preliminary efficacy of allogeneic Wharton's jelly-mesenchymal stem cell-derived extracellular vesicles (EVs) in patients with acute ischemic stroke.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| SNE-101 | Experimental | Drug: SNE-101Patients will be given SNE-101, an extracellular vesicle derived from Wharton's jelly mesenchymal stem cells. • Drug: SNE-101 * Three multiple doses of SNE-101 will be administered to three study cohorts , each consisting of 3 to 6 subjects. * SNE-101 will be administered intravenously once a day for 5 days. |
Who may qualify
- Ages
- 19 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Adults with 19 years or older
- Patients within 5 days of symptom onset who have not received thrombolytic therapy or undergone endovascular reperfusion procedures.
- Patients within 5 days of symptom onset who have received thrombolytic therapy or undergone endovascular reperfusion procedures but show no clinical recovery after 2 days of observation.
- Imaging findings must meet both of the following:
- Neurological status meeting all three of the following NIHSS criteria:
Key exclusion criteria (21 listed)
- Pre-stroke disability (pre-stroke mRS ≥ 2)
- Likely to recover spontaneously, based on all three of:
- Presence or risk of malignant middle cerebral artery infarction with brain edema
- Significant medical history within the past 5 years:
- Diagnosed severe psychiatric illness:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SNE-101Experimental: Cohort 1 - SNE-101 4.8 × 10e10 particles (n=3 to 6) Experimental: Cohort 2 - SNE-101 9.6 × 10e10 particles (n=3 to 6) Experimental: Cohort 3 - SNE-101 19.2 × 10e10 particles (n=3 to 6) | Drug | SNE-101 |
Primary outcome
To evaluate the safety and tolerability of SNE-101 in patients with acute ischemic stroke and determine the Maximum Tolerated Dose (MTD)
Time frame: MTD: within 19 days after first dose
o The Maximum Tolerated Dose (MTD) determination via the Dose limiting toxicity (DLT)
To evaluate the safety and tolerability of SNE-101 in patients with acute ischemic stroke and determine the Maximum Tolerated Dose (MTD)
Time frame: Adverse events: 180 days
o Adverse events are monitored continuously throughout the study.
5 secondary outcomes
To assess the efficacy of SNE-101 in patients with acute ischemic stroke.
Time frame: 13 weeks
To assess the efficacy of SNE-101 in patients with acute ischemic stroke.
Time frame: 13 weeks
To assess the efficacy of SNE-101 in patients with acute ischemic stroke.
Time frame: 13 weeks
To assess the efficacy of SNE-101 in patients with acute ischemic stroke.
Time frame: 13 weeks
To assess the efficacy of SNE-101 in patients with acute ischemic stroke.
Time frame: 13 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jul 2026.
Related trials for Acute Ischemic Stroke AIS
Not yet recruitingPhase 2/3
A Phase II/III Clinical Study of SIM0811 in the Treatment of Acute Ischemic Stroke
Acute Ischemic Stroke AIS
Not yet recruitingPhase 3
Metformin in Acute Ischemic Stroke
Acute Ischemic Stroke
RecruitingObservational study
FORWARD: Functional Outcomes in Real-World Treatment And Revascularization of Non-dominant and Distal M2 Occlusions
Acute Ischemic Stroke, Acute Ischemic Stroke (AIS) Related to a Distal Occlusion
RecruitingPhase 2
A Study to Evaluate the Intracranial Arterial Recanalization With Multiple Doses of LT3001 Drug Product in AIS Participant
Acute Ischemic Stroke
RecruitingPhase 3
ACT-GLOBAL IA Thrombolysis(ACT-REACT-004)Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
Stroke, Acute Ischemic, Endovascular Thrombectomy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing SNE-101 in people with Acute Ischemic Stroke AIS, run by S&Ebio Co. Ltd. at 3 sites in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Oh Young Bang, MD, Ph.D (+82-2-2054-8128, ohyoung.bang@snebio.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To evaluate the safety and tolerability of SNE-101 in patients with acute ischemic stroke and determine the Maximum Tolerated Dose (MTD) (time frame: MTD: within 19 days after first dose). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jul 2026.